Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII | Medizinische Tipps Online

Medizinische Tipps Online

  •  

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

January 03, 2020

No single drug is effective for every patient, and there is great variability in toxicity and price, ranging from about $400 to $15,000 a year. Bridges says the next major advance needed in the treatment of RA is not additional drugs, but, rather, a dramatic improvement in the efficiency and cost-effectiveness of the use of current drugs for individual patients with RA.

"TETRAD will fill a critical need by aligning and uniting the efforts of many organizations with the common goal of improving care for RA patients," Bridges said. "By unifying the efforts of academic researchers, we can create resources that would not otherwise be available, such as a bank of cryo-preserved blood cells to enable sophisticated immunologic research to dissect molecular signals of successful treatment of RA."

Source: University of Alabama at Birmingham